Wellington Management Group LLP Increases Stock Holdings in Bio-Rad Laboratories, Inc. $BIO

Wellington Management Group LLP lifted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 191.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,359 shares of the medical research company's stock after acquiring an additional 1,549 shares during the period. Wellington Management Group LLP's holdings in Bio-Rad Laboratories were worth $575,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of BIO. Curat Global LLC purchased a new position in shares of Bio-Rad Laboratories during the first quarter worth approximately $34,000. Allworth Financial LP grew its position in shares of Bio-Rad Laboratories by 260.0% during the first quarter. Allworth Financial LP now owns 144 shares of the medical research company's stock worth $36,000 after acquiring an additional 104 shares during the last quarter. Headlands Technologies LLC grew its position in shares of Bio-Rad Laboratories by 64.1% during the first quarter. Headlands Technologies LLC now owns 356 shares of the medical research company's stock worth $87,000 after acquiring an additional 139 shares during the last quarter. Skylands Capital LLC purchased a new position in shares of Bio-Rad Laboratories during the first quarter worth approximately $122,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Bio-Rad Laboratories during the first quarter worth approximately $206,000. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Price Performance

Bio-Rad Laboratories stock traded up $5.84 during midday trading on Friday, reaching $295.27. The company's stock had a trading volume of 257,890 shares, compared to its average volume of 211,765. Bio-Rad Laboratories, Inc. has a fifty-two week low of $211.43 and a fifty-two week high of $387.99. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.67 and a current ratio of 5.12. The stock's 50 day simple moving average is $268.80 and its 200 day simple moving average is $251.78. The firm has a market capitalization of $7.99 billion, a PE ratio of 25.17 and a beta of 0.95.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its earnings results on Thursday, July 31st. The medical research company reported $2.61 EPS for the quarter, beating analysts' consensus estimates of $1.93 by $0.68. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%.The company had revenue of $651.60 million during the quarter, compared to the consensus estimate of $614.82 million. During the same quarter last year, the company earned $3.11 earnings per share. Bio-Rad Laboratories's quarterly revenue was up 2.1% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on BIO. Wall Street Zen lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, August 22nd. Royal Bank Of Canada increased their price target on Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an "outperform" rating in a report on Friday, August 1st. Zacks Research raised Bio-Rad Laboratories from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 26th. Finally, Wells Fargo & Company increased their price target on Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Three research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Bio-Rad Laboratories has a consensus rating of "Moderate Buy" and a consensus price target of $333.50.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.